On Janurary 7th, 2025, Annals of Oncology (IF: 56.7), a top oncology journal globally, published remarkable long-term ...

English teachers might have told students the word "each" is pronoun that gets a singular verb, but that's only part of the ...

PostEra, a biotechnology company specializing in machine learning for preclinical drug discovery, today announced an expansion of their partnership with Pfizer. The parties will launch a new ...

Two anti-transferrin receptor (TfR) nanobodies, V H H123 specific for mouse TfR and V H H188 specific for human TfR (huTfR) were used to track transplants non-invasively by PET/CT in mouse models, ...

With new treatments in neurology, and more in development in cardiology and autoimmune diseases, precision medicine is moving ...

Geode Capital Management LLC grew its position in Pyxis Oncology, Inc. (NASDAQ:PYXS – Free Report) by 5.5% in the third ...

Brown’s little-known acquisition of Hitler’s personal library and the debate over what these books can or cannot reveal.

Roche's strategic changes in drug development and M&A activity may drive future growth, despite recent setbacks in clinical ...

ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs ...

Roche has once again returned to China to bolster its antibody-drug conjugate pipeline, this time striking a licensing deal ...

Roche Holding AG kicked off the new year (again) with a potential $1 billion deal, including $80 million up front, for exclusive rights to Innovent Biologics Inc.’s IBI-3009, a DLL3-targeting antibody ...

The antibody-drug conjugate showed a higher objective response rate but failed to meet the primary OS endpoint in patients ...